CN110896636B - 抑制mps1激酶的化合物的盐、其制备以及包含它的制剂 - Google Patents

抑制mps1激酶的化合物的盐、其制备以及包含它的制剂 Download PDF

Info

Publication number
CN110896636B
CN110896636B CN201880043442.0A CN201880043442A CN110896636B CN 110896636 B CN110896636 B CN 110896636B CN 201880043442 A CN201880043442 A CN 201880043442A CN 110896636 B CN110896636 B CN 110896636B
Authority
CN
China
Prior art keywords
cancer
tumors
lymphoma
treatment
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880043442.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN110896636A (zh
Inventor
M·扎皮耶里
M·卡尔达雷利
I·坎迪安尼
M·达内洛
G·达拉斯摩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nerviano Medical Sciences SRL
Original Assignee
Les Laboratoires Servier SAS
Nerviano Medical Sciences SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Les Laboratoires Servier SAS, Nerviano Medical Sciences SRL filed Critical Les Laboratoires Servier SAS
Publication of CN110896636A publication Critical patent/CN110896636A/zh
Application granted granted Critical
Publication of CN110896636B publication Critical patent/CN110896636B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201880043442.0A 2017-06-29 2018-06-28 抑制mps1激酶的化合物的盐、其制备以及包含它的制剂 Active CN110896636B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17305826 2017-06-29
EP17305826.4 2017-06-29
PCT/EP2018/067394 WO2019002454A1 (en) 2017-06-29 2018-06-28 NOVEL N- (2,6-DIETHYLPHENYL) -8 - ({4- [4- (DIMETHYLAMINO) PIPERIDIN-1-YL] -2-METHOXYPHENYL} AMINO) -1-METHYL-4,5-DIHYDRO-1H SALT -PYRAZOLO [4,3-H] QUINAZOLINE-3-CARBOXAMIDE, ITS PREPARATION AND FORMULATIONS CONTAINING THE SAME

Publications (2)

Publication Number Publication Date
CN110896636A CN110896636A (zh) 2020-03-20
CN110896636B true CN110896636B (zh) 2022-07-19

Family

ID=59313166

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880043442.0A Active CN110896636B (zh) 2017-06-29 2018-06-28 抑制mps1激酶的化合物的盐、其制备以及包含它的制剂

Country Status (19)

Country Link
US (3) US11160806B2 (enExample)
EP (1) EP3645535B1 (enExample)
JP (1) JP7141416B2 (enExample)
KR (1) KR102609333B1 (enExample)
CN (1) CN110896636B (enExample)
AR (1) AR112040A1 (enExample)
AU (1) AU2018293729B9 (enExample)
CA (1) CA3068357C (enExample)
CL (1) CL2019003848A1 (enExample)
EA (1) EA039764B1 (enExample)
ES (1) ES2900048T3 (enExample)
IL (1) IL271628B2 (enExample)
MA (1) MA49498A (enExample)
PL (1) PL3645535T3 (enExample)
PY (1) PY1850855A (enExample)
SG (1) SG11201912651WA (enExample)
TW (1) TWI750393B (enExample)
UY (1) UY37778A (enExample)
WO (1) WO2019002454A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025002962A1 (en) 2023-06-30 2025-01-02 Nerviano Medical Sciences S.R.L. Use of a mps1 inhibitor for the treatment of hepatocellular carcinoma
WO2025021587A1 (en) 2023-07-21 2025-01-30 Nerviano Medical Sciences S.R.L. Combination of a mps1 inhibitor and immune checkpoint inhibitors, uses and pharmaceutical compositions thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009156315A1 (en) * 2008-06-26 2009-12-30 Nerviano Medical Sciences S.R.L. Pyrazolo-quinazolines

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009156315A1 (en) * 2008-06-26 2009-12-30 Nerviano Medical Sciences S.R.L. Pyrazolo-quinazolines

Also Published As

Publication number Publication date
ES2900048T3 (es) 2022-03-15
MA49498A (fr) 2021-05-26
US11160806B2 (en) 2021-11-02
KR20200020905A (ko) 2020-02-26
IL271628B1 (en) 2023-03-01
AU2018293729B9 (en) 2022-07-14
UY37778A (es) 2019-01-31
US20220016122A1 (en) 2022-01-20
CN110896636A (zh) 2020-03-20
SG11201912651WA (en) 2020-01-30
EA202090115A1 (ru) 2020-05-25
KR102609333B1 (ko) 2023-12-01
EP3645535B1 (en) 2021-09-08
PY1850855A (es) 2019-04-01
TW201904971A (zh) 2019-02-01
US20240350501A1 (en) 2024-10-24
JP2020525477A (ja) 2020-08-27
EA039764B1 (ru) 2022-03-11
CL2019003848A1 (es) 2020-07-10
IL271628B2 (en) 2023-07-01
US20200246339A1 (en) 2020-08-06
EP3645535A1 (en) 2020-05-06
AU2018293729B2 (en) 2022-03-10
CA3068357A1 (en) 2019-01-03
WO2019002454A1 (en) 2019-01-03
PL3645535T3 (pl) 2022-03-21
TWI750393B (zh) 2021-12-21
AR112040A1 (es) 2019-09-11
CA3068357C (en) 2022-04-19
JP7141416B2 (ja) 2022-09-22
AU2018293729A1 (en) 2020-01-23
BR112019027924A2 (pt) 2020-08-18
IL271628A (en) 2020-02-27

Similar Documents

Publication Publication Date Title
CN111148745B (zh) Fgfr抑制剂的结晶形式及其制备方法
US10016427B2 (en) Hydrochloride salt of((1S,2S,4R)-4-{4-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-7H-pyrrolo[2,3-D]pyrimidin-7-YL}-2-hydroxycyclopentyl) methyl sulfamate
KR20190120458A (ko) 결정질의 (8s,9r)-5-플루오로-8-(4-플루오로페닐)-9-(1-메틸-1h-1,2,4-트리아졸-5-일)-8,9-디하이드로-2h-피리도[4,3,2-de]프탈라진-3(7h)-온 토실레이트 염
US20240350501A1 (en) SALT OF N-(2,6-DIETHYLPHENYL)-8-({4-[4-(DIMETHYLAMINO) PIPERIDIN-1-YL]-2-METHOXYPHENYL}AMINO)-1-METHYL-4,5-DIHYDRO-1H-PYRAZOLO[4,3-h]QUINAZOLINE-3-CARBOXAMIDE, ITS PREPARATION, AND FORMULATIONS CONTAINING IT
WO2019120194A1 (zh) 一种取代的吡唑并[1,5-a]嘧啶化合物及其药物组合物及用途
JP7430656B2 (ja) Ｃｄｋ４／６活性阻害化合物の結晶形およびその使用
WO2019134573A1 (zh) 一种氘代二苯氨基嘧啶类化合物的制备方法及其晶型
HK40022862B (en) Salt of a compound inhibiting mps1 kinase, its preparation and formulations containing it
HK40022862A (en) Salt of a compound inhibiting mps1 kinase, its preparation and formulations containing it
US20240368165A1 (en) Solid state forms of hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo[2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate
TW202342041A (zh) 一種藥物組合物及所含活性成分化合物的製備方法
BR112019027924B1 (pt) Fosfato de n-(2,6-dietilfenil)-8-({4-[4-(dimetilamino)piperidin-1-il]-2- metoxifenil}amino)-1-metil-4,5-di-hidro-1h-pirazolo[4,3-h]quinazolina-3- carboxamida, processo para a sua obtenção, composição farmacêutica, combinação e seus usos
RU2723990C2 (ru) Кристаллическая форма (s)-n-(5-((r)-2-(2,5-дифторфенил)-пирролидин-1-ил)-пиразоло[1,5-a]пиримидин-3-ил)-3-гидроксипирролидин-1-карбоксамида гидросульфата

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40022862

Country of ref document: HK

TA01 Transfer of patent application right

Effective date of registration: 20210719

Address after: Milano, Italy

Applicant after: NERVIANO MEDICAL SCIENCES S.R.L.

Address before: Suresne, France

Applicant before: LES LABORATOIRES SERVIER

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant